NCT06165146View on ClinicalTrials.gov

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions

Healthy

Interventions

DRUG

Repaglinide

Administered orally.

DRUG

Pirtobrutinib

Administered orally.

Trial Locations (1)

32117

Covance Clinical Research Unit, Daytona Beach

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06165146 - A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants | Biotech Hunter | Biotech Hunter